The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy

BJU International

Volumn 98, Issue 3, 2006, Pages 540-543

  Taylor III, John A ^a   Koff, Stacey G ^b   Dauser, Deborah A ^a   McLeod, David G ^b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Prostate cancer; PSA; Recurrence; Ultrasensitive analysis

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 33746869275     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06294.x     Document Type: Article

References (13)

1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16
2. Vessella RL. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity. Clin Chem 1993; 39: 2035-9
3. Stamey TA, Graves HC, Wehner N, Ferrari M, Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993; 149: 787-92
4. Ferguson RA, Yu H, Kalyvas M, Zammit S, Diamandis EP. Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 1996; 42: 675-84
5. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate-specific antigen used for early detection of prostate cancer relapse and estimation of tumor-doubling time after radical prostatectomy. Clin Chem 1995; 41: 430-4
6. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141: 873-9
7. Junker R, Brandt B, Semjonow A, Erren M, Zechel C, Assmann G. The biologic lower detection limit of six ultrasensitive PSA assays. Anticancer Res 1999; 19: 2625-8
8. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 1997; 50: 573-9
9. De Geeter F. Parameters relating to ultrasensitive prostate-specific antigen assays. Clin Chem 1997; 43: 2010-1
10. Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001-0.1 microG./L. J Urol 1997; 157: 913-8
11. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
12. Doherty AP, Bower M, Smith GL et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer 2000; 83: 1432-6
13. Albertsen PC, Hanley JA, Penson DF, Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 2004; 171: 2221-5